You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

Citation Tools

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials in-progress
800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Eigentler T, Heinzerling L, Krauss J, et al
800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0800